AlloVir, Baylor collaborate to develop COVID-19 T-cell therapy

AlloVir, a clinical stage T-cell immunotherapy company, will work with Baylor College of Medicine to develop allogeneic, virus-specific T-cell therapy to combat COVID-19 , according to a news release. “Our objective is to develop a potent, coronavirus-targeted T-cell product that is safe for patients and has the potential to […]

Click here to view original web page at

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.